Partial Bridging of Vaccine Efficacy to New Populations
Alexander R. Luedtke, Peter B. Gilbert

TL;DR
This paper proposes a method to estimate vaccine efficacy in new populations using existing trial data and biomarker information, addressing challenges in bridging efficacy results when direct trials are infeasible.
Contribution
It introduces a partial identification approach for marginal efficacy based on bounds of unvaccinated risk, with a nonparametric estimator and confidence bounds.
Findings
Provides a curve of lower bounds for efficacy in new populations.
Develops a nonparametric estimator with confidence bounds.
Applicable to binary interventions and bounded outcomes.
Abstract
Suppose one has data from one or more completed vaccine efficacy trials and wishes to estimate the efficacy in a new setting. Often logistical or ethical considerations make running another efficacy trial impossible. Fortunately, if there is a biomarker that is the primary modifier of efficacy, then the biomarker-conditional efficacy may be identical in the completed trials and the new setting, or at least informative enough to meaningfully bound this quantity. Given a sample of this biomarker from the new population, we might hope we can bridge the results of the completed trials to estimate the vaccine efficacy in this new population. Unfortunately, even knowing the true conditional efficacy in the new population fails to identify the marginal efficacy due to the unknown conditional unvaccinated risk. We define a curve that partially identifies (lower bounds) the marginal efficacy in…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVaccine Coverage and Hesitancy · Influenza Virus Research Studies · Hepatitis C virus research
